Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Harvard Business School
Colorcon
Federal Trade Commission
Teva

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,865,937

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,865,937 protect, and when does it expire?

Patent 8,865,937 protects FETZIMA and is included in one NDA.

This patent has eight patent family members in four countries.

Summary for Patent: 8,865,937
Title:Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.
Inventor(s): Dedhiya; Mahendra G. (Pomona, NY), Surana; Rahul (Commack, NY)
Assignee:
Application Number:12/941,293
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,865,937
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Process;

Drugs Protected by US Patent 8,865,937

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-003 Jul 25, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-004 Jul 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,865,937

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2779711 ➤ Sign Up
Canada 2790933 ➤ Sign Up
European Patent Office 2496079 ➤ Sign Up
European Patent Office 2536688 ➤ Sign Up
Japan 2013510176 ➤ Sign Up
Japan 2013517290 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2011057176 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
Queensland Health
Moodys
US Army
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.